Offered by the , the Damon Runyon-Rachleff Innovation Award provides support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact understanding of and/or approaches to the prevention, diagnosis, and treatment of cancer.
The award provides funding to extraordinary early-career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. Research supported by the award must be novel, exceptionally creative, and, if successful, have great potential for high impact in the cancer field.
Basic and translational/clinical projects will be considered, as will joint submissions from two collaborators working in different disciplines.
Awards will be paid in increments of $200,000 per year for two years will be awarded, with an opportunity for up to two additional years of funding.
To be eligible, applicants must be conducting independent research at a U.S. research institution, although they need not be a U.S. citizen. Applicants must have received an MD, PhD, or MD/PhD degree(s) from an accredited institution.
See the Damon Runyon Cancer Research Foundation for complete program guidelines and application instructions.